Seeking Alpha

Shane Skinner's  Instablog

Shane Skinner
Send Message
Shane Skinner has invested in biotech companies for almost 20 years and placed over $2.6 million in biotech stock trades in 2013. He has held various financial leadership positions over the past 17 years throughout the United States and Europe including Chief Financial Officer. Shane graduated... More
My blog:
  • Trade Updates - Aveo BioPharma And Bind Therapeutics 2 comments
    Mar 19, 2014 4:43 PM | about stocks: AVEO, BIND, PFE, AMGN, AZN

    Aveo (NASDAQ:AVEO) - Purchased 4,000 shares at $1.69. I don't necessary feel great about the companies near term prospects but they had approximately $120 million in cash at the end of the year and their current book value is $87 million so I felt it was a good value play. They have an opportunity to in-license or hope for some positive developments in their preclinical program. I'm selling back at $1.90.

    Bind (NASDAQ:BIND) - Purchased 1,000 shares at $12.10. The company went public last year at $15 and is running two phase 2 trails of it's lead compound in Lung and Prostate cancer with results expected later this year. They had over $80 million in cash at the end of Q3 and three outstanding partnerships - Amgen, Pfizer, and AstraZeneca. With a market cap just under $200 million, this seemed like a great buy at this price.

    Disclosure: I am long AVEO, BIND.

    Themes: Biotech Stocks: AVEO, BIND, PFE, AMGN, AZN
Back To Shane Skinner's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (2)
Track new comments
  • ciolan
    , contributor
    Comments (193) | Send Message
    I too am long BIND and holding on. The showdown will be this year, definitely. Are you buying more?
    15 Apr 2014, 02:26 PM Reply Like
  • Shane Skinner
    , contributor
    Comments (37) | Send Message
    Author’s reply » I have no current plans to buy more but I do like the company, it's partnerships, and the two phase 2 trials in prostate and lung cancer that should report this year. If the sector continues to take a dive and Bind continues to get dragged down with the sector, I'll probably buy more.
    18 Apr 2014, 01:20 AM Reply Like
Full index of posts »
Latest Followers


More »

Latest Comments

Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.